Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5030802 | 0.99 | KMT2A (0.63) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL697928 | 0.92 | KMT2A (0.73) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL693424 | 0.92 | KMT2A (0.69) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| Hydrochloric Acid SCHEMBL693423 | 0.91 | KMT2A (0.67) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL18376140 | 0.89 | KMT2A (0.64) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL20126921 | 0.88 | KMT2A (0.60) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL92796 | 0.87 | KMT2A (0.66) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL31419531 | 0.87 | KMT2A (0.66) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL31305073 | 0.86 | KMT2A (0.62) | KMT2AEPHX2CASP3CXCR2FABP5 | |
| SCHEMBL422645 | 0.86 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20130190248-A1 | SUBSTITUTED PEPTIDE ANALOGS | AGENSYS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | SIGNATURE THERAPEUTICS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2008101202-A1 | N-17-ALKYLATED PRODRUGS OF OPIOIDS | PHARMACOFORE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190248-A1 | SUBSTITUTED PEPTIDE ANALOGS | NGLY1, VIP, DNPEP | KMT2A 2205/4885EPHX2 3286/4885CASP3 1285/4885 |
| US-20240207363-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | SGMS1, SGMS2, PHOSPHO1 | KMT2A 3238/4885EPHX2 1256/4885CASP3 388/4885 |
| US-20120142718-A1 | N-17-Alkylated Prodrugs of Opioids | OPRM1, OPRD1, OPRL1 | KMT2A 827/4885EPHX2 872/4885CASP3 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.